From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“必须说服买家考虑”的候选者转变为“已批准、指定、列入、合格、注册、报销或预先授权”的选择,从而进入买方的采购、报销、处方集、规格、采购、网络、目录或计划系统,使得未来业务的一部分可以无需每次单独销售就能到达,并且管理层传达这种准入状态是新的,大部分由此带来的量尚未反映在报告结果中。 在记录中,管理层提到了几个合作伙伴关系,例如与Tribal Group的“首选支付合作伙伴协议”,以及与Ascensus的529计划合作。这些可能被视为进入买方系统的途径。但我们需要检查是否明确表示这种状态是新的,并且大部分量尚未实现。 具体来看: - 关于Tribal Group:管理层说“我们宣布与Tribal Group达成首选支付合作伙伴协议”,这听起来像是被列入首选名单,但未明确说明这是否是新的,或者是否大部分量尚未实现。 - 关于Ascensus:管理层提到“我们与Ascensus的合作以及围绕529计划所做的工作”,但同样未明确说明这是否是新的准入状态。 此外,管理层提到“我们正在接近50个教育领域的公司集成”,这可能是进入系统的方式,但未明确说明这是否是新的。 在回答中,管理层没有明确说“我们最近被添加到某个名单中,因此未来业务将自动流入”这样的表述。他们更多是在描述客户增加和合作伙伴关系,但未强调这种准入状态是新的且大部分量尚未实现。 因此,根据指示,如果只是普通的销售关系或标准客户胜利,则答案为NO。这里似乎没有明确描述公司已进入买方系统并成为默认选择,且大部分量尚未实现。 所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.